Unlock critical evidence to accelerate access to cancer treatments worldwide

Broad patient access to treatments requires demonstrating value to payers and HTA bodies. With so much at stake, payer evidence packages and HTA submissions need to be grounded in the strongest evidence available.

Get started

Case Studies

NICE used Flatiron RWD as a comparator arm to support its positive recommendation for elacestrant to treat patients with ER-positive HER2-negative advanced breast cancer with an ESR1 mutation that has progressed after at least one line of endocrine treatment.

Clinico-genomic RWD from Flatiron and Foundation Medicine was used to support the approval of trastuzumab in Japan for the treatment of unresectable advanced or recurrent HER2-positive colorectal cancer that has progressed after initial chemotherapy.

Confident market access decisions start with real-world clarity

outcome-variables

Real-world data

Our high-fidelity RWD has all the scale, breadth, depth, timeliness, and quality you need to develop rigorous, trustworthy evidence for your HTA dossier in key markets.

bar chart

AI-powered insights

Flatiron Telescope, our AI-powered intelligence platform, allows you to access the evidence you need to develop powerful insights using an intuitive natural language interface and analytical capabilities.

multi-disciplinary

Expertise

We’ve worked with NICE, FDA's OCE, and other leading global HTA bodies for years, and we know how to navigate the complex submission process and address their concerns upfront.

How market access teams are using Flatiron’s data

  • Natural history studies

  • Burden of illness analyses

  • Comparative effectiveness assessments

  • Indirect treatment comparisons

  • Overall support with payer and HTA submissions

Flatiron at the forefront of RWE transportability research

Payers, regulators, and HTA bodies increasingly require local evidence to support market access. When local data is insufficient or inaccessible, critical decisions stall.

We launched Flatiron FORUM, a global consortium of HTA bodies, biopharma leaders, and academic experts, to explore how RWE from one country can inform decisions in another — reshaping our cross-border understanding of cancer care and paving the way for a new framework in HTA decision-making.

flatiron-forum

“Through the combined strength of Flatiron's global oncology research network and Flatiron FORUM, we are unlocking richer insights for both local innovation and multinational research — ultimately supporting more informed clinical breakthroughs, regulatory decisions, and better outcomes for patients across the UK and worldwide.”

Professor Geoff Hall

Chief Clinical Information Officer

Leeds Teaching Hospitals NHS Trust, UK

by the numbers

15+

years of longitudinal oncology data

4

large oncology markets: US, UK, Germany, Japan

10+

years partnership with FDA and NICE

45+

global regulatory decisions supported by Flatiron RWD

Flatiron’s market access solutions in action

Connect with Flatiron’s market access experts

Request a meeting